New drug cocktail aims to beat back multiple myeloma

NCT ID NCT03710603

Ongoing Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding daratumumab to a standard three-drug regimen (VRd) improves outcomes for people with newly diagnosed multiple myeloma who can undergo high-dose therapy. About 709 participants will receive either the four-drug combo or the standard three drugs. The main goal is to see if the new combination delays disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab (a targeted antibody) combined with bortezomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this combination could improve long-term control of multiple myeloma and delay disease progression.
What could go wrong: This is an advanced trial, but results may not apply to all patients. Side effects from the drug combination can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Alfred Hospital

Melbourne, Australia
Ankara University

Ankara, Turkey (Türkiye)
Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona

Ancona, Italy
CHRU Hôtel Dieu

Nantes, France
Erasmus MC

Rotterdam, Netherlands
Hospital Clinic I Provincial de Barcelona

Barcelona, Spain
Kantonsspital St. Gallen

Sankt Gallen, Switzerland
Odense University Hospital

Odense, Denmark
Oslo University Hospital

Oslo, Norway
Regional General Hospital Alexandra

Athens, Greece
University Hospital Leuven

Leuven, Belgium
University Hospital Ostrava

Ostrava, Czechia
Uniwersytet Jagiellonski Collegium Medicum

Krakow, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.